ESMO 2019 | MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancer

George Sledge, MD, of Stanford University, Stanford, CA, presents the MONARCH 2 overall survival results at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. The trial (NCT02107703) investigated the combination of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer.